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Abstract
Hepatitis C virus (HCV) and alcoholic liver disease (ALD), either alone or in combination, count 
for more than two thirds of all liver diseases in the Western world. There is no safe level of 
drinking in HCV-infected patients and the most effective goal for these patients is total abstinence. 
Baclofen, a GABAB receptor agonist, represents a promising pharmacotherapy for alcohol 
dependence (AD). Previously, we performed a randomized clinical trial (RCT), which 
demonstrated the safety and efficacy of baclofen in patients affected by AD and cirrhosis. The goal 
of this post-hoc analysis was to explore baclofen's effect in a subgroup of alcohol-dependent HCV-
infected cirrhotic patients. Any patient with HCV infection was selected for this analysis. Among 
the 84 subjects randomized in the main trial, 24 alcohol-dependent cirrhotic patients had a HCV 
infection; 12 received baclofen 10mg t.i.d. and 12 received placebo for 12-weeks. With respect to 
the placebo group (3/12, 25.0%), a significantly higher number of patients who achieved and 
maintained total alcohol abstinence was found in the baclofen group (10/12, 83.3%; p=0.0123). 
Furthermore, in the baclofen group, compared to placebo, there was a significantly higher increase 
in albumin values from baseline (p=0.0132) and a trend toward a significant reduction in INR 
levels from baseline (p=0.0716). In conclusion, baclofen was safe and significantly more effective 
than placebo in promoting alcohol abstinence, and improving some LFTs (i.e. albumin, INR) in 
alcohol-dependent HCV-infected cirrhotic patients. Baclofen may represent a clinically relevant 
alcohol pharmacotherapy for these patients.
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1. Introduction
Alcohol represents one of the most common causes of liver cirrhosis in the Western world. 
Furthermore, alcohol dependence (AD) represents an independent risk factor for hepatitis C 
virus (HCV) infection (Mendenhall et al., 1993; Rosman et al., 1996) and the prevalence of 
HCV is 3- to 30-fold higher in alcoholic individuals compared with the general population 
(Singal and Anand, 2007). HCV and alcoholic liver disease (ALD), either alone or in 
combination, count for more than two thirds of all liver diseases in the Western world 
(Mueller et al, 2009). Alcohol consumption accelerates HCV-related liver disease and the 
co-existence of both alcohol consumption and HCV result in a synergistic effect (but see: 
Anand and Thornby, 2005). For example, consumption of 50g/day of alcohol increased the 
rate at which fibrosis progresses in HCV-infected individuals (Poynard et al., 1997), and the 
risk factor for developing cirrhosis was significantly higher in HCV-infected patients that 
abused alcohol, compared to those who did not consume alcohol (Corrao and Arico', 1998). 
Indeed, even moderate alcohol consumption may turn into progressive liver fibrosis (Westin 
et al., 2002). Therefore, there is no safe level of drinking in HCV-infected patients and the 
most effective goal for these patients is to achieve total alcohol abstinence (Mueller et al., 
2009).
Pharmacotherapies represent important therapeutic tools in AD (Leggio et al, 2010a), but 
randomized clinical trials (RCTs) with alcohol pharmacotherapies typically exclude patients 
with significant liver diseases because of extensive liver metabolism of some of these drugs 
and/or the risk of drug-related hepatotoxicity. Indeed, both disulfiram and naltrexone carry 
on a risk for hepatotoxicity, especially if administered to patients with liver diseases (Chick, 
1999; Mosby's Drug Consult, 2005). Baclofen, a GABAB receptor agonist, represents a 
promising novel alcohol pharmacotherapy (Leggio et al., 2010b). Consistent with preclinical 
studies (reviewed in: Maccioni and Colombo, 2009), the majority of the clinical studies 
suggest baclofen's efficacy in AD (Addolorato et al., 2000, 2002, 2006, 2011; Flannery et 
al., 2004; Leggio et al., 2008a,b; but see: Garbutt et al, 2010). Indeed, our group performed a 
RCT with baclofen in patients affected by AD and cirrhosis, which demonstrated the safety 
and efficacy of baclofen in this specific population (Addolorato et al., 2007). Compared to 
placebo, more patients assigned baclofen achieved and maintained alcohol abstinence 
throughout the study. Also, individuals treated with baclofen, compared to placebo, had 
significantly greater improvement in biomarkers of liver injury, i.e. alanine aminotransferase 
(ALT), aspartate transaminase (AST), and in liver function tests (LFTs), i.e. albumin, 
international normalized ratio (INR) and bilirubin.
The goal of the present post-hoc analysis was to explore if baclofen's effect was still present 
in a subgroup of alcohol-dependent HCV-infected cirrhotic patients, and if there were 
differences in baclofen's safety and response among HCV-infected and HCV-negative 
patients.
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2. Methods
2.1. Brief Overview of the Main RCT
For a detailed description of the main trial, see Addolorato et al. (2007). Briefly, inclusion 
criteria included age range of 18-75 years, and diagnoses of AD and cirrhosis. Exclusion 
criteria included, among the others, medical and/or psychiatric contraindications to take 
baclofen. Notably, the presence of HCV infection was not exclusion. Eighty-four patients 
were randomized to receive either placebo or baclofen 10mg t.i.d. for 12 weeks. Patients 
were seen each week for the first month, and then every other week. At each visit, 
psychological counselling was also provided. The study was conducted at the Alcohol 
Treatment Unit, Catholic University of Rome (Italy), it was approved by the local Ethics 
Committee and registered in ClinicalTrials.gov (NCT00525252).
2.2. Patients and Methods
Out of the 84 patients enrolled in the main RCT (Addolorato et al., 2007), any patient with 
HCV infection was selected for this post-hoc analysis. The goal of this analysis was to 
explore the effects of baclofen, as compared to placebo, on total alcohol abstinence, and on 
ALT, AST and LFTs in alcohol-dependent HCV-infected cirrhotic patients. An additional 
goal was to compare the HCV-infected subgroup with the rest of the sample (i.e. HCV-
negative) to investigate possible differences between the two groups in terms of safety and 
response to baclofen.
2.3 Statistical Analysis
All discrete variable were reported as percentage and compared between the two treatment 
groups or in HCV-infected and negative group with the Fisher's exact test. The continuous 
variables were expressed as median and corresponding interquartile range and compared by 
means of U-Mann Whitney test. All analyses were carried out with SAS software, version 
9.1. For all tested hypotheses, two-tailed p-values less than 0.05 were considered to be 
significant.
3. Results
3.1. Demographics and baseline characteristics of the HCV-infected sub-group
Among the 84 subjects randomized in the main trial, 24 (29%) alcohol-dependent cirrhotic 
patients had a HCV infection. Out of these 24 alcohol-dependent HCV-infected cirrhotic 
patients, 12 received baclofen 10mg t.i.d. and 12 received placebo for 12-weeks. The 
baseline characteristics of the HCV-infected sub-group are outlined in the Table 1. No 
significant difference was found in the number of drop-outs between baclofen and placebo 
groups [2 out of 12 patients (16.7%) vs. 3 out of 12 patients (25.0%) respectively; p=1.000, 
Fisher's exact test].
3.2. Differences at baseline between HCV-infected and HCV-negative patients
A comparison of the HCV-infected vs. HCV-negative patients showed no differences in all 
baseline demographics characteristics and blood tests, with the exception of significantly 
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higher baseline ALT (p=0.0095) and AST (p=0.0192) levels in the HCV-infected than in the 
HCV-negative patients.
3.3. Effects of Baclofen on Alcohol and Liver Outcomes in alcohol-dependent HCV-infected 
cirrhotic patients
As displayed in Figure 1, with respect to the placebo group (3 out of 12, 25.0%), a 
significantly higher number of patients who achieved and maintained total alcohol 
abstinence was found in the baclofen group (10 out of 12, 83.3%; p=0.0123, Fisher's exact 
test). When considering only subjects who completed the study the statistic was still 
significant (p=0.0055).
Treatment with baclofen resulted in a clinical improvement in LFTs, i.e. in the baclofen 
group, compared to placebo, there was a significantly higher increase in albumin values 
from baseline (p=0.0132) and a trend toward a significant reduction in INR levels from 
baseline (p=0.0716). No significant difference in AST, ALT, GGT, MCV and creatinine 
values was found between baclofen and placebo group (p>0.05).
Finally, as in the main trial, no clinically significant side-effects were reported, and no 
patient discontinued the drug. The side-effects were vertigo (1 patient), tiredness (1 patient), 
sleepiness (1 patient), headache (1 patient), in the baclofen group and headache (3 patients), 
fatigue (1 patient) and vertigo (1 patient) in the placebo group.
4. Discussion
This analysis demonstrates that baclofen was significantly more effective than placebo in 
promoting alcohol abstinence, and improving some LFTs (i.e. albumin, INR) in alcohol-
dependent HCV-infected cirrhotic patients. Though a very small sample, the most relevant 
finding of this study is that baclofen demonstrated its efficacy and safety in promoting total 
alcohol abstinence in this subgroup of patients. The co-existence of alcohol and HCV, as 
compared to either condition alone, dramatically increases the risk of developing severe liver 
diseases, i.e. fibrosis, cirrhosis and hepatocellular carcinoma. Not only is heavy drinking 
deleterious for the liver in HCV-infected patients, but also moderate alcohol consumption 
may aggravate liver disease in HCV-infected patients (Westin et al., 2002). As a matter of 
fact, the National Institute for Alcohol Abuse and Alcoholism (NIAAA; see NIAAA webite) 
highlights that even ‘light-to-moderate’ drinking (≥2 drinks/day for males; ≥1 drinks/day for 
females) may be “too much” in some conditions, including HCV infection.
As there are no safe levels of alcohol consumption in HCV-infected individuals, total alcohol 
abstinence represents a very important goal to achieve for alcohol-dependent HCV-infected 
patients. Pharmacotherapies, in conjunction with psychological approaches, may represent 
effective tools for clinicians. This study shows that while all patients received psychological 
counseling during the study, adding baclofen resulted in a significant improvement in 
alcohol abstinence. Therefore, this study suggests baclofen may represent a clinically 
relevant alcohol pharmacotherapy for these patients, a feature of particular importance if we 
consider that alcohol pharmacotherapy trials typically exclude patients with clinically 
significant liver diseases.
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Though a small sample (n = 24), our study demonstrated that treatment with baclofen, 
compared to placebo, resulted in a significant improvement in some LFTs (albumin and 
INR). Notably, the impairment of these parameters represents a very important factor for 
clinically relevant complications, such as ascites (albumin) and bleeding (INR).
Consistent with the main trial (Addolorato et al., 2007), this analysis showed the safety of 
baclofen, when administered to alcohol-dependent HCV-infected cirrhotic patients, 
including the complete lack of hepatic or renal side-effects. Baclofen is mainly excreted 
unmodified by the kidney (Davidoff, 1985), therefore possible changes in the renal function 
in baclofen-treated patients would be an important concern. In this study, no subjects 
experienced increased creatinine levels, nor were differences found in creatinine levels 
between the two groups. This was expected given the exclusion criteria (i.e. any kidney 
disease, including hepato-renal syndrome), and the lack of renal side-effects in the whole 
sample (Addolorato et al., 2007). Nevertheless, given that in addition to the liver, HCV may 
lead to extra-hepatic manifestations, including the kidney (e.g. membranoproliferative 
glomerulonephritis associated with Type 2 cryoglobulinemia) (Kamar et al, 2008), this study 
still provides important safety information, i.e. the lack of changes in renal function in 
alcohol-dependent HCV-infected cirrhotic patients treated with baclofen.
In the parent study, we found a significant improvement in ALT (and LFTs) in baclofen-
treated patients (Addolorato et al., 2007). Here, it is highly likely that the presence of HCV 
infection was responsible for the significantly higher baseline ALT and AST levels, as 
compared to the HCV-negative patients, and for the lack of a significant improvement in 
ALT levels in the baclofen group (in spite of a significant improvement in two clinically 
important LFTs, i.e. albumin and INR). It is possible that longer treatment with baclofen 
might reveal an improvement in markers of liver injury (i.e. ALT, AST) in this sub-group, 
therefore longer prospective studies will be required to address this.
Certainly the improvement in LFTs in the baclofen group was due to the ability of baclofen 
to stop alcohol drinking. Therefore, when AD and HCV infection co-exist, ideally the best 
approach will be to combine a safe alcohol pharmacotherapy (e.g. baclofen) that promotes 
abstinence and improve liver function (i.e. LFTs), together with antiviral therapies that 
reduce the viral load and improve hepatic injury (i.e. ALT). As such, future studies may 
consider combining baclofen and antiviral therapies, and/or using baclofen as an alcohol 
treatment ‘bridge’ before starting HCV therapies. In fact, heavy alcohol consumption 
represents a relative contraindication for antiviral therapies (Soriano et al., 2007). However, 
with appropriate treatment, coinfected people deemed at first ineligible for HCV therapy can 
become eligible (Adeyemi et al., 2004; Mehta et al., 2005). Therefore, baclofen may play an 
important role as an alcohol treatment in the context of antiviral HCV therapies, and this is 
an even more important goal to pursue if we consider the recent approval of new antiviral 
therapies.
These data also suggest that an additional area to explore will be the potential for baclofen to 
be used for alcohol-dependent HCV-infected cirrhotic patients (the same kind of population 
analyzed here) who need orthotopic liver transplantation (OLT), but for which current 
alcohol consumption represents a contraindication (see: Burra and Lucey, 2005). Addressing 
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alcohol consumption in alcohol-dependent HCV-infected cirrhotic patients who need an 
OLT is particularly important, given that these patients are more likely to die on the waiting 
list than those with either ALD or HCV alone, but after transplantation, non-risk adjusted 
graft and survival of alcohol-dependent HCV-infected patients are comparable to those of 
patients with HCV or ALD alone (Carbone & Neuberger, 2010).
The present analysis has some significant limitations, i.e. the post-hoc kind of analysis, the 
very small sample, and the lack of additional data on HCV (i.e. genotype and HCV-RNA). 
Nonetheless, this study provides significant preliminary information, which suggests the 
need to perform a large prospective RCT with baclofen to treat AD in HCV-infected 
patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Figure 1 shows that, with respect to the placebo group (3 out of 12, 25.0%), a significantly 
higher number of alcohol-dependent HCV-infected cirrhotic patients achieved and 
maintained total alcohol abstinence in the baclofen group (10 out of 12, 83.3%; p=0.0123, 
Fisher's exact test).
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Table 1
Demographic and addiction characteristics of the sub-group of alcohol-dependent cirrhotic patients with HCV 
infection (n = 24).
Baclofen group (n = 12) Placebo group (n= 12) P-value
Median of Age (Interquartile range) 47.0 (43.0-60.0) 53.5 (44.0-60.0) 0.6295
Male n (%) 10 (83.3%) 7 (58.3%) 0.3707
Married n (%) 8 (66.7%) 8 (66.7%) 1.000
Education > 13 years n (%) 2 (16.7%) 6 (50.0%) 0.1930
Employed n (%) 8 (66.7%) 11 (91.7%) 0.3168
Median of daily consumption (drinks) of alcohol in years (Interquartile 
range) 16.0 (12.0-28.0) 21.0 (13.0-24.5) 0.9447
Median of duration of alcohol addiction in years (Interquartile range) 19.0 (16.5-23.5) 20.5(17.5-29.0) 0.5214
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